Listen to this article

Teva Pharmaceuticals launched the first generic version of Revlimid, a treatment for myelodysplastic syndrome, multiple myeloma, and mantle cell lymphoma.

Myelodysplastic syndrome is a group of disorders caused when something disrupts the production of blood cells; multiple myeloma is a cancer that forms in plasma cells; and mantle cell lymphoma is a rare type of B cell non-Hodgkin lymphoma.

Teva launched its generic version of Revlimid, also known as lenalidomide capsules, in 5 mg, 10 mg, 15 mg, and 25 mg strengths nationwide.

“The launch of our first generic version of Revlimid in the U.S. provides patients with another important treatment option for these extremely challenging conditions, demonstrating Teva’s commitment to making complex generic drugs available to the patients who need them,” said Christine Baeder, senior vice president and chief operating officer of Teva’s U.S. generics arm. “This product adds to our broad generic portfolio of oncology treatments, which accounts for 73% of the essential medicines in this category, as defined by the World Health Organization.”

Revlimid had annual sales of $2.3 billion as of December 2021, according to IQVIA data. Teva manufactures 550 generic medicines in the nation; currently, 1 in 12 generic prescriptions dispensed in the U.S. is filled with a Teva generic product.